Evoke Pharma, Inc. (EVOK)

Over the past six months, Evoke Pharma's stock price has experienced significant increases, including a rise of 209.71% over the last six months. Key events include the announcement of its acquisition by QOL Medical, which caused the stock to soar. The company reported GAAP EPS of -$0.45 and revenue of $4.28M on November 13, 2025. A study of Gimoti in GLP-1 users led to a 90% increase in the stock price. Evoke Pharma announced proceeds from existing warrants and an expansion of its board. The stock surged after the company announced a new patent. Evoke Pharma's shares tumbled to a 52-week low of $3.49.

Analysis of Evoke Pharma Inc. (EVOK) stock suggests some seasonality in its returns. Historically, buying EVOK stock in June has shown the highest probability of a positive return, while March has demonstrated the lowest probability of a positive return.

Evoke Pharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing drugs for gastrointestinal disorders, operating in the Healthcare sector. Its primary product, Gimoti, is a metoclopramide nasal spray designed to treat symptoms of diabetic gastroparesis in adults. The company markets its products to various healthcare providers and was incorporated in 2007, with its headquarters in Solana Beach, California.

Evoke Pharma, Inc. is based in Solana Beach, California, and primarily focuses its marketing efforts on healthcare providers within the United States.

Evoke Pharma's reputation has been influenced by its financial performance and strategic corporate developments. The company has reported strong revenue growth for Gimoti, indicating growing adoption and trust in its product. The appointment of Greg Pyszczymuka to its Board of Directors reflects a proactive approach to enhancing its market position. The company also faced challenges, such as a cyberattack and increased co-pay expenses, which marginally impacted net revenue. Despite operational hurdles and a stock price dip, the company's strong balance sheet and revenue growth suggest a resilient operational standing.

Evoke Pharma, Inc. has a diverse ownership structure, including institutional and individual investors. Major institutional owners include Morgan Stanley, Nantahala Capital Management, LLC, Bleichroeder LP, National Wealth Management Group, LLC, DRW Securities, LLC, Vanguard Group Inc, Two Sigma Securities, Llc, FSMAX - Fidelity Extended Market Index Fund, Advisor Group Holdings, Inc., and VEXMX - Vanguard Extended Market Index Fund Investor Shares. Institutions hold approximately 20.89% of common stock, while individuals/insiders hold about 8.07%.